FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia - PubMed (original) (raw)
Randomized Controlled Trial
. 2014 Nov;29(11):2075-84.
doi: 10.1093/ndt/gfu201. Epub 2014 Jun 2.
Affiliations
- PMID: 24891437
- PMCID: PMC4209879
- DOI: 10.1093/ndt/gfu201
Randomized Controlled Trial
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
Iain C Macdougall et al. Nephrol Dial Transplant. 2014 Nov.
Abstract
Background: The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown.
Methods: Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with non-dialysis-dependent CKD, anaemia and iron deficiency not receiving erythropoiesis-stimulating agents (ESAs). Patients were randomized (1:1:2) to intravenous (IV) ferric carboxymaltose (FCM), targeting a higher (400-600 µg/L) or lower (100-200 µg/L) ferritin or oral iron therapy. The primary end point was time to initiation of other anaemia management (ESA, other iron therapy or blood transfusion) or haemoglobin (Hb) trigger of two consecutive values <10 g/dL during Weeks 8-52.
Results: The primary end point occurred in 36 patients (23.5%), 49 patients (32.2%) and 98 patients (31.8%) in the high-ferritin FCM, low-ferritin FCM and oral iron groups, respectively [hazard ratio (HR): 0.65; 95% confidence interval (CI): 0.44-0.95; P = 0.026 for high-ferritin FCM versus oral iron]. The increase in Hb was greater with high-ferritin FCM versus oral iron (P = 0.014) and a greater proportion of patients achieved an Hb increase ≥1 g/dL with high-ferritin FCM versus oral iron (HR: 2.04; 95% CI: 1.52-2.72; P < 0.001). Rates of adverse events and serious adverse events were similar in all groups.
Conclusions: Compared with oral iron, IV FCM targeting a ferritin of 400-600 µg/L quickly reached and maintained Hb level, and delayed and/or reduced the need for other anaemia management including ESAs. Within the limitations of this trial, no renal toxicity was observed, with no difference in cardiovascular or infectious events.
Clinicaltrialsgov number: NCT00994318.
Keywords: anaemia; chronic kidney disease.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA.
Figures
FIGURE 1:
Enrolment and outcomes. The ITT population comprised all patients who received at least one dose of randomized treatment, or according to the protocol were not treated due to ferritin level, and attended at least one post-baseline visit. The safety population included all patients who received at least one dose of randomized treatment, and included 154 patients in the high-ferritin FCM group, 150 patients in the low-ferritin FCM group and 312 patients in the oral iron group. Two patients randomized to the low-ferritin FCM group met the eligibility requirements at screening but did not require FCM during the study according to the protocol-specified criteria for ferritin. These two patients were included in the ITT population but excluded from the safety population.
FIGURE 2:
(A) Time to initiation of other anaemia management or Hb trigger (Kaplan–Meier estimates) and LS mean locally measured observed values over time for (B) Hb (C) ferritin and (D) TSAT according to treatment group (ITT population). Measurements of Hb, ferritin and TSAT were included up to the point at which other anaemia therapy was initiated (with or without cessation of randomized study drug) and/or the patient discontinued the study. BL, baseline; FCM, ferric carboxymaltose.
Comment in
- Anaemia: FIND-CKD: intravenous iron in predialysis CKD.
Fishbane S, Hazzan AD. Fishbane S, et al. Nat Rev Nephrol. 2014 Sep;10(9):488-9. doi: 10.1038/nrneph.2014.139. Epub 2014 Aug 5. Nat Rev Nephrol. 2014. PMID: 25092153 No abstract available.
Similar articles
- The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators. Macdougall IC, et al. Nephrol Dial Transplant. 2014 Apr;29(4):843-50. doi: 10.1093/ndt/gft424. Epub 2013 Oct 29. Nephrol Dial Transplant. 2014. PMID: 24170814 Free PMC article. Clinical Trial. - Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD; FIND-CKD Study investigators. Macdougall IC, et al. BMC Nephrol. 2017 Jan 17;18(1):24. doi: 10.1186/s12882-017-0444-6. BMC Nephrol. 2017. PMID: 28095881 Free PMC article. Clinical Trial. - Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Cronin M, Meier Y, Larroque S, Macdougall IC; FIND-CKD Study Investigators. Roger SD, et al. Nephrol Dial Transplant. 2017 Sep 1;32(9):1530-1539. doi: 10.1093/ndt/gfw264. Nephrol Dial Transplant. 2017. PMID: 28339831 Free PMC article. Clinical Trial. - Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA, Keating GM. Lyseng-Williamson KA, et al. Drugs. 2009;69(6):739-56. doi: 10.2165/00003495-200969060-00007. Drugs. 2009. PMID: 19405553 Review. - Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.
Toblli JE, Angerosa M. Toblli JE, et al. Drug Des Devel Ther. 2014 Dec 11;8:2475-91. doi: 10.2147/DDDT.S55499. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25525337 Free PMC article. Review.
Cited by
- Advances of Iron and Ferroptosis in Diabetic Kidney Disease.
Chu J, Wang K, Lu L, Zhao H, Hu J, Xiao W, Wu Q. Chu J, et al. Kidney Int Rep. 2024 Apr 3;9(7):1972-1985. doi: 10.1016/j.ekir.2024.04.012. eCollection 2024 Jul. Kidney Int Rep. 2024. PMID: 39081773 Free PMC article. Review. - A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy.
Gupte S, Mukhopadhyay A, Puri M, Gopinath PM, Wani R, Sharma JB, Swami OC. Gupte S, et al. Rev Bras Ginecol Obstet. 2024 Mar 15;46:e-rbgo21. doi: 10.61622/rbgo/2024AO21. eCollection 2024. Rev Bras Ginecol Obstet. 2024. PMID: 38765534 Free PMC article. Review. - Anemia in Pregnancy With CKD.
de Jong MFC, Nemeth E, Rawee P, Bramham K, Eisenga MF. de Jong MFC, et al. Kidney Int Rep. 2024 Jan 11;9(5):1183-1197. doi: 10.1016/j.ekir.2024.01.015. eCollection 2024 May. Kidney Int Rep. 2024. PMID: 38707831 Free PMC article. Review. - Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.
Stoumpos S, Crowe K, Sarafidis P, Barratt J, Bolignano D, Del Vecchio L, Małyszko J, Więcek A, Ortiz A, Cozzolino M. Stoumpos S, et al. Nephrol Dial Transplant. 2024 Sep 27;39(10):1710-1730. doi: 10.1093/ndt/gfae075. Nephrol Dial Transplant. 2024. PMID: 38573822 Free PMC article. Review. - Functional iron deficiency anemia was associated with higher mortality in chronic kidney disease patients: the NHANES III follow-up study.
Gong W, Huang J, Zhu T, Lin S, Hao C, Zhang M. Gong W, et al. Ren Fail. 2023;45(2):2290926. doi: 10.1080/0886022X.2023.2290926. Epub 2023 Dec 7. Ren Fail. 2023. PMID: 38059456 Free PMC article.
References
- K idney Disease Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2:292–298.
- Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590. - PubMed
- Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084. - PubMed
- Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098. - PubMed
- Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical